Research Advances in Nanodrugs Targeting Lipid Metabolism Reprogramming for Colorectal Cancer Therapy Authors: Jingwen Tang, Mengnan Liu, Ruizhi Zhang, Qiang Li, Shengtao Wang, Yuehua Wang Published: 2026 ABSTRACT AbstractColorectal cancer (CRC) remains a major global health burden, with limited efficacy of conventional treatments due to tumor heterogeneity, drug resistance, and systemic toxicity. Lipid metabolism reprogramming has emerged as a hallmark of CRC progression, influencing tumor growth, metastasis, and therapy resistance. Concurrently, nanomedicine offers innovative platforms for targeted drug delivery to to inhibit tumor progression by intervening in the lipid metabolism, including modulation of lipid synthesis, uptake, storage, and cholesterol metabolism. This review provides an integrated perspective, systematically summarizing therapeutic strategies and research progress on nanodrugs targeting lipid metabolic reprogramming in CRC. We highlight nanoplatforms engineered to deliver inhibitors of key enzymes and signaling pathways, such as PI3K/AKT and Wnt/β-catenin. Representative nanoplatforms are discussed to illustrate diverse strategies for regulating lipid metabolic vulnerabilities in CRC, such as carrier-free nanoparticles, RBC membrane-coated nanocages and cholesterol-responsive nanoparticles. We also discuss the challenges in clinical translation, including tumor heterogeneity, biosafety, large-scale production, and clinical validation. Furthermore, we provide insight into translational challenges, emerging trends, and future directions for integrating lipid-targeted nanotherapies into clinical practice.Keywords: CRC treatment, nanoparticle, abnormal lipid metabolism, signaling pathway, precision nanomedicine Introduction CRC is a common malignant tumor which severely threatens human health, ranking third in global cancer incidence.1,2 Recently, the diagnosis and treatment of CRC have achieved significant improvement, but the global 5-year overall survival for CRC patients remains approximately 50%, and the survival rate for metastatic cases is less than 15%.3 The main reason is that CRC usually presents with no clear symptoms in the initial phase. Most CRC patients are diagnosed at an advanced stage, and the cancer even has metastasized. Nevertheless, the mechanism driving CRC initiation and malignant progression has not been fully elucidated, and further studies are required to delineate the key molecular events of tumorigenesis and progression, as well as the driving factors of metastatic invasion. The occurrence of CRC mainly arises from genetic and environmental factors, containing the age, family history, excess weight and dysbiosis.4,5 In addition, tumor cell metabolic reprogramming also drives CRC initiation and progression. Among the various metabolic abnormalities, lipid metabolism disorder plays an important role in remodeling the tumor microenvironment (TME) and promoting CRC progression.6 The main features of lipid metabolic reprogramming include enhanced lipid uptake, upregulated lipid synthesis, increased fatty acid oxidation (FAO), and abnormal lipid storage.7 In CRC cells, the key enzymes of lipid metabolism are significantly upregulated, leading to a large production of lipids like fatty acids, phospholipids, and cholesterol. These lipids are the main building blocks of cell membranes. They can satisfy the tumor cells’ need for membrane biosynthesis during their proliferation, thus supporting CRC cell survival and growth. Lipids also mediate cell membrane signal transduction, participating in the activation of signaling pathways such as PI3K/AKT and Wnt/β-catenin. Consequently, they regulate metabolic reprogramming in tumor cells and promote the development of malignant phenotypes in CRC cells. Furthermore, various constituents of TME regulate lipid metabolism. Immune cells sustain their immune function through the upregulation of lipid metabolism, while cancer-associated fibroblasts (CAFs) and adipocytes provide metabolic raw materials for colorectal cancer cells by secreting fatty acids.8 This lipid supply accelerates CRC cell invasion and metastasis. Therefore, targeting critical steps in lipid metabolism holds promise to suppress CRC progression and metastasis, making lipid metabolic pathways a highly attractive therapeutic intervention target. Recently, numerous studies have indicated that targeting key enzymes or transporters involved in lipid metabolism may represent a potential therapeutic approach for CRC. Hence, in-depth elucidation of the molecular regulatory network of lipid metabolic reprogramming is essential for clarifying the mechanisms of CRC pathogenesis, achieving early diagnosis, and devising precision therapeutic strategies. The traditional therapies for CRC include surgical resection, chemotherapy, radiotherapy, and immunotherapy (Figure 1), with specific therapeutic strategies adopted according to tumor staging and genotyping.9 These therapies improve survival to some extent, but still have many limitations. Surgery is mainly used for early and locally advanced colorectal cancer, but patients with locally advanced stage have a high risk of recurrence after surgical resection, with a 5-year recurrence rate of 30–50%.10,11 For patients with advanced colorectal cancer, chemotherapy and radiotherapy are important adjuvant treatment strategies.12,13 Chemotherapy prevents the expansion of residual cancer cells after surgery, effectively reducing the risk of tumor recurrence. Common chemotherapy drugs such as oxaliplatin and 5-fluorouracil weaken the antitumor effect due to rapid clearance and non-specific administration, and cause adverse reactions such as nausea, diarrhea, neurotoxicity, and bone marrow suppression.14 For unresectable colorectal cancer, radiotherapy lowers the clinical stage and makes the tumor resectable, creating conditions for subsequent radical surgery. However, the ionizing radiation produced during radiotherapy can damage the surrounding normal tissues and induce complications such as radiation enteritis.15 Immunotherapy leverages immune checkpoint inhibitors to activate the antitumor activity of patients’ T cells, enabling them to recognize and kill cancer cells.16 However, the efficacy of immunotherapy varies considerably among individuals, and its high cost limits clinical use. Therefore, it is urgent to explore therapeutic approaches with high efficacy and low toxicity to achieve precision treatment of CRC. Schematic overview of conventional therapeutic approaches for CRC, including surgical resection, chemotherapy, radiotherapy, and immunotherapy. The symbol “×” indicates the limitations associated with the corresponding therapeutic approach. As an emerging therapeutic strategy, nanomedicine offers a safer and more effective option for colorectal cancer treatment by virtue of its enhanced targeting, stability, and tumor accumulation capability. This class of therapeutics mainly includes liposomes, polymeric nanoparticles, metallic nanoparticles, exosomes, and others.17 Conventional targeted therapy focuses on specific single molecular targets, and is often limited by tumor heterogeneity, compensatory pathway activation, and acquired resistance. In contrast, targeting lipid metabolic reprogramming may provide a broader therapeutic strategy by simultaneously intervening in multiple key metabolic processes, including fatty acid synthesis, β-oxidation, and membrane remodeling. This multi-dimensional regulatory capability may help overcome the limitations of conventional targeted therapy, offering a more promising approach for CRC therapy. Previous reviews have summarized nanomedicine-based therapeutic strategies for CRC or the biological mechanisms of lipid metabolic reprogramming in cancer. However, an integrated perspective that systematically combines nanodrugs with targeted lipid metabolism therapeutic strategies has not yet been comprehensively reviewed. This review addresses this gap by comprehensively summarizing recent advances in nanodrugs targeting lipid metabolism reprogramming for CRC treatments. In this review, we discuss the application potential of nanodrugs in improving the therapeutic efficacy of lipid metabolism inhibitors. We further outline current challenges and future directions, providing guidance for the development of novel CRC treatment strategies and their clinical translation. Nanodrugs Targeting Lipid Metabolism Reprogramming Lipid metabolism reprogramming is a key feature of CRC metabolic abnormalities. It promotes tumor cell growth, proliferation, invasion, and metastasis through multiple mechanisms. This process plays a critical role in cancer initiation and progression. The pathways of lipid metabolism reprogramming primarily involve the uptake of exogenous lipids, de novo synthesis of endogenous lipids, remodeling of cholesterol metabolism, and the storage and catabolic mobilization of lipid droplets for energy production (Figure 2). Meanwhile, these pathways are directly regulated by multiple oncogenic signaling pathways, with which they form positive feedback loops. Nanodrugs exert antitumor effects through diverse targeting pathways. Representative nanoplatforms targeting lipid metabolism reprogramming are summarized in Table 1. Schematic illustration of key regulators involved in lipid metabolism reprogramming. Table 1Representative Nanoplatforms Targeting Lipid Metabolism ReprogrammingPathwayTargetNanoparticle CompositionTargeting StrategyExperimental ModelTherapeutic EfficacyTranslational LimitationsDevelopment StageRefLipid synthesisACLYCarrier-free NPs, co-delivery (DOX/NDI-091143)CAF metabolic targetingCAFs; tumor-bearing miceReduced ECM and enhanced tumor penetration/chemotherapyStability and scale-upPreclinical[18]Lipid synthesisACCRBC-coated nanocage, CRISPR+ND-630GPC3-targeted RBCMHepG2; HCC miceEnhanced lipid peroxidation, ferroptosis and tumor inhibitionCRISPR safety and manufacturing complexityPhase 2[19]Lipid synthesisFASNCarrier-free NPs, co-delivery (RSL3/Orlistat)Redox-responsive releaseBreast cancer cells; 4T1 miceEnhanced ferroptosis and antitumor efficacyTumor heterogeneity and systemic effectsPreclinical[20]Lipid uptakeCD36HA@CD36i-TR@siSCD1, co-delivery (a CD36 inhibitor/siSCD1)HA/CD44 + RGD/αvβ3Resistant prostate cancer; miceBlocked lipid uptake/synthesis and suppressed tumor growthComplex formulation and siRNA deliveryPreclinical[21]Cholesterol metabolismHMGCRCSNPs (cholesterol-responsive cargo-switching nanoparticles), cyclodextrin nanoparticles loaded with simvastatinCholesterol-affinity targetingAtherosclerotic miceReduced plaque cholesterol and promoted regressionLong-term safety and human heterogeneityPhase 2&3[22]Cholesterol metabolismACATMMP-2-responsive tumor-penetrable nanovesicles loaded with avasimibeMMP-2-responsive iRGDB16-F10 melanoma; miceEnhanced PDT/immunotherapy and tumor inhibitionLight penetration and MMP-2 dependencePreclinical[23]Notes: Studies conducted in non-CRC models are included as representative evidence of the feasibility of lipid metabolism-targeted nanomedicine. Representative Nanoplatforms Targeting Lipid Metabolism Reprogramming Notes: Studies conducted in non-CRC models are included as representative evidence of the feasibility of lipid metabolism-targeted nanomedicine. Targeting Lipid Synthesis De novo lipogenesis (DNL) is crucial for maintaining cellular lipid homeostasis. Lipogenic enzymes play a central role in regulating lipid synthesis. They control the synthesis of fatty acid (FA), chain elongation, and desaturation to maintain lipid metabolic balance.24 However, these enzymes show abnormally high expression in malignant tumors, leading to excessive activation of lipid synthesis and promoting rapid tumor cell proliferation.25 ATP citrate lyase (ACLY) is the initiating enzyme of DNL. It catalyzes the decomposition of citrate into acetyl-CoA and oxaloacetate acid, providing the key precursor for fatty acid synthesis.26 The overexpression or increased activity of ACLY correlates with CRC malignant progression.27 Studies have shown that ACLY promotes CRC metastasis and invasion by facilitating β-catenin nuclear accumulation and enhancing its transcriptional activity.28 However, due to the diverse origins of citrate, selective targeting of ACLY alone may trigger metabolic compensation mechanisms, thereby compromising the antitumor efficacy. Acetyl-CoA carboxylase (ACC) serves as the rate-limiting enzyme in fatty acid synthesis, mediating the conversion of acetyl-CoA to malonyl-CoA. This process is associated with poor CRC prognosis.29 PPARδ, a lipid-sensing nuclear receptor, shows enhanced nuclear localization through ACC1-driven lipogenesis in intestinal epithelial cells. PPARδ and β-catenin cooperatively activate Wnt signaling pathway to maintain intestinal stem cell function and promote CRC development.30 Fatty acid synthase (FASN) is the terminal synthase of DNL. It catalyzes malonyl-CoA to produce palmitate, which serves as the exclusive precursor for the synthesis of all saturated fatty acid (SFA) and downstream monounsaturated fatty acid (MUFA).31 Therefore, elevated FASN expression ensures a continuous supply of palmitate, which promotes fatty acid synthesis and consequently supports the CRC cell growth.32 Notably, CAFs with elevated FASN secrete more fatty acids, facilitating CRC cell migration.33 While aberrant lipid synthesis is a central feature of metabolic reprogramming in CRC, it is not the sole factor. The malignant progression of tumors also requires the integrated actions of multiple pathways, including lipid uptake, oxidation, and storage. Nanodrugs that regulate lipid synthesis offer significant advantages. By leveraging nanoparticle technology to achieve precise drug delivery, they address key challenges associated with conventional drugs, such as poor solubility, limited targeting capability, and high toxicity. Multiple studies have revealed the crucial role of lipogenic enzymes in tumor occurrence and development from various perspectives. Researchers have developed targeted intervention strategies that demonstrate excellent tumor suppression effects. Due to the widespread availability of citrate, the upstream substrate of ACLY, solely targeting ACLY can easily trigger metabolic compensatory mechanisms, thereby diminishing the antitumor efficacy. Therefore, ACLY inhibitors need to be used in combination with other therapeutic agents. Yu et al18 developed a carrier-free nanoagent (CFNA) that co-delivers the ACLY-specific inhibitor NDI-091143 with chemotherapeutic drugs (Figure 3A). This nanoplatform specifically targets CAFs in the tumor microenvironment. By inhibiting ACLY-mediated fatty acid synthesis, it effectively disrupts CAFs energy metabolism and enhances tumor drug penetration. The strength of this nanoplatform is its ability to overcome the tumor stromal barrier, whereas the in vivo stability of carrier-free self-assembled nanoparticles remains to be validated. Zhao et al19 constructed peptide-modified red blood cell membrane‑coated nanocages (NTA630‑NCs‑RBCM‑T) for the co‑delivery of CRISPR‑Cas9 and the small‑molecule ACC1 inhibitor ND-630 (Figure 3B). Through the dual action of gene editing and chemical inhibition, this nanoplatform reduces ACC1 expression levels, thereby decreasing fatty acid synthesis. Concurrently, this process promotes the uptake of polyunsaturated fatty acid (PUFA), triggers lipid peroxidation, and induces ferroptosis, leading to tumor cell apoptosis, thus exerting potent antitumor effects. This nanoplatform combines two agents to produce a synergistic therapeutic effect. Compared with small‑molecule ACC inhibitor monotherapy, CRISPR‑Cas9 gene editing technology enables irreversible functional knockout. Wu et al20 designed a lipid nano-regulator which co‑assembles RSL3 with the FASN inhibitor orlistat (Figure 3C). By leveraging orlistat to increase the PUFA content in cell membranes and synergizing with RSL3‑induced GPX4 depletion, this nanoplatform cooperatively enhances lipid peroxidation, effectively bypassing the ferroptosis defense mechanisms of tumor cells and improving antitumor efficacy. Nanomedicine strategies targeting lipid metabolism to enhance cancer therapy. (A) Schematic illustration of the construction of CFNA and the disruption of tumor stromal barriers. (i) Self-assembly of CFNA from doxorubicin, paclitaxel, and NDI-091143 through intermolecular interactions. (ii) CFNA-mediated ACLY inhibition remodels CAFs, reduces ECM production, enhances tumor penetration, and promotes OSCC cell death. Adapted with permission from,18 copyright 2024 American Chemical Society. (B) Intelligent nano-cage for precision delivery of CRISPR-Cas9 and ACC inhibitors to enhance antitumor therapy through lipid metabolism disruption. Targeted ACC1 inhibition disrupts fatty acid synthesis, promotes PUFA accumulation and peroxidation, and induces ferroptosis. Adapted with permission from,19 copyright 2025 Wiley-VCH Verlag GmbH and Co. KGaA. (C) Schematic presentation of a self-engineered lipid nanoregulator for ferroptosis-driven tumor treatment. (i) GPX4 inhibition-induced ROS accumulation and increased unsaturated phospholipid levels promote ferroptosis. (ii) FASN inhibition and PUFA-PL remodeling increase lipid peroxidation and ROS accumulation, resulting in ferroptotic cell death. Adapted with permission from,20 copyright 2024 Elsevier. Symbols: “↓” indicates decreased levels or activity; “↑” indicates increased levels or activity; “⦸” indicates inhibition or blockade. The aforementioned nanodrugs targeting lipid synthesis have demonstrated significant advantages in the CRC treatment. By targeting key lipogenic enzymes such as ACLY, ACC1, and FASN, and combining them with chemotherapeutic agents, CRISPR‑Cas9, or ferroptosis inducers, these nanoplatforms achieve synergistic antitumor effects, offering novel avenues for CRC therapy. These intervention strategies show clear potential for clinical translation. Nanodrugs based on ACLY inhibitor NDI-091143 and FASN inhibitor Orlistat are currently at the preclinical stage, requiring further validation of their antitumor efficacy and safety. In contrast, ACC inhibitors like ND-630 are currently in Phase II trials for metabolic diseases, showing strong promise for being adapted into cancer treatment. Targeting Lipid Uptake In addition to de novo synthesis, CRC cells also acquire fatty acids by enhancing exogenous lipid uptake to meet their metabolic demands of rapid proliferation. This process is mainly mediated by various membrane-associated transport proteins and is one of the key features of tumor lipid metabolic reprogramming. The fatty acid transporter CD36, a key receptor highly expressed in CRC, supports tumor cell growth and metastasis by promoting lipid uptake and fatty acid oxidation.34,35 Studies reveal that CD36-overexpressing CRC cells exhibit greater invasiveness and metastatic potential. CD36 upregulates metallopeptidase MMP28 expression, leading to E-cadherin cleavage, which weakens cell-cell adhesion and enhances metastatic capacity.36 Clinical data show that CD36 protein expression is closely correlated with the clinicopathological features of CRC, patients overexpressing CD36 mRNA faced a lower 5-year survival rate.37 Therefore, targeting the CD36-MMP28 signaling pathway may represent a potential therapeutic strategy to inhibit CRC metastasis. The fatty acid transport proteins (FATPs) family plays crucial roles in long-chain fatty acid uptake and metabolic regulation, primarily participating in fatty acid activation and storage, thereby influencing tumor initiation and progression.38 These proteins localize to the plasma membrane or intracellular membranes connected to the endoplasmic reticulum, regulating fatty acid transport. Research has shown that FATP1, FATP2 and FATP4 are classified as targets for small-molecule inhibitors aimed at reducing cellular fatty acid uptake.39 FATPs are considered novel therapeutic targets for metabolic diseases and cancer, their inhibitors protect the kidneys and liver from lipid overload while suppressing immunosuppressive cells in TME.40 Fatty acid binding proteins (FABPs) similarly play significant roles in CRC. FABPs bind and store long-chain fatty acids, transporting these ligands to appropriate intracellular compartments.41 Multiple studies demonstrate that FABPs actively contribute to CRC development and progression. Overexpression of FABP5 in CRC cells significantly enhances their proliferative and metastatic capabilities, while FABP4 promotes malignant progression by activating epithelial-mesenchymal transition (EMT).42 Studies have shown that knocking down FABPs inhibits CRC cell proliferation and induces apoptosis. Chen et al21 developed a multi-response nanodrug HA@CD36i-TR@siSCD1 (Figure 4A). This innovative nanoplatform features a hyaluronic acid (HA) gel shell and cationic micelle core structure. It achieved the triple-responsive drug release of acidic microenvironment, hyaluronidase and glutathione and collaboratively inhibited CD36-mediated exogenous lipid uptake and SCD1-regulated endogenous lipid synthesis. This nanodrug demonstrated outstanding tumor-targeting capability and tissue penetration, significantly suppressing tumor growth, invasion, and metastasis. Although this platform was originally evaluated in a prostate cancer model, its HA targeting and dual lipid metabolism inhibition mechanisms are relevant to CRC therapy. The findings indicate that disrupting tumor lipid uptake is also a viable therapeutic strategy. In the future, the possibility of combining lipid uptake‑related inhibitors with chemotherapeutic agents could be explored to enhance treatment efficacy. Nanomedicine strategies targeting lipid metabolism for therapeutic applications. (A) Schematic illustration of the establishment and mechanism of the HA@CD36i-TR@siSCD1 nanoplatform. (i) Construction of the HA@CD36i-TR@siSCD1 nanoplatform. (ii) Proposed antitumor mechanism of HA@CD36i-TR@siSCD1, including (a) multiresponsive drug release, (b) regulation of lipid metabolism, and (c) regulation of the immuno-microenvironment. The roman numerals i–vi indicate the sequential processes of i, tumor accumulation and delivery; ii, HAase-mediated degradation of hyaluronic acid and pH-responsive nanoparticle disassembly; iii, CD36 inhibition and suppression of fatty acid uptake and PPAR-β signaling; iv, αvβ3-mediated uptake of TA@siSCD1 by cancer cells; v, endo-lysosomal processing; and vi, siSCD1-mediated SCD1 mRNA silencing, resulting in reduced MUFA production. Adapted with permission from,21 copyright 2025 Wiley-VCH GmbH. (B) Schematic illustration of CSNP preparation, cargo switching, cholesterol dissolution, and synergistic anti-atherosclerotic effects. Adapted with permission from,22 copyright 2020 American Chemical Society. (C) Schematic illustration of the design and antitumor mechanism of MMP-2-sensitive nanovesicles (EALP). (i) EALP composition, systemic circulation, tumor accumulation, and deep tumor penetration. (ii) EALP-mediated inhibition of ACAT-1 in T cells and modulation of cholesterol esterification. (iii) EALP uptake by tumor cells and subsequent inhibition of ACAT-1/SREBP2 signaling, induction of immunogenic cell death, and activation of antitumor immunity. Adapted with permission from,23 copyright 2022 Wiley-VCH GmbH. Symbols: “↓” indicates decreased levels or activity; “↑” indicates increased levels or activity; “⦸” indicates inhibition or blockade; “×” indicates inhibition of ACAT-1 activity. Targeting Cholesterol Metabolism Cholesterol metabolism plays a critical role in the development and progression of CRC. Cancer cells regulate the uptake, storage, and release of cholesterol to sustain their rapid proliferation and invasive growth. Elevated cholesterol levels and abnormal accumulation of its metabolites accelerate tumor growth while promoting immune evasion.43,44 Intracellular cholesterol synthesis occurs through the mevalonate (MVA) pathway using acetyl-CoA as a precursor. The key rate-limiting enzyme in this process is HMG-CoA reductase (HMGCR). This enzyme is regulated by the SREBP2 transcription factor and is overexpressed in CRC. Its elevated expression supplies multiple forms of cholesterol for biosynthesis.45,46 Key enzymes in the MVA pathway offer potential therapeutic targets for inhibiting cholesterol production. In addition to endogenous synthesis pathway, cells obtain exogenous cholesterol from LDL via the low-density lipoprotein receptors (LDLR).47 LDLR is upregulated in various cancers and it facilitates cholesterol uptake. When intracellular cholesterol levels rise, acyl-CoA cholesterol acyltransferase (ACAT) converts the excess cholesterol into less toxic cholesteryl esters (CEs). These neutral lipids are then stored in lipid droplets (LDs).48 Although this storage process reduces cholesterol toxicity, sustained cholesterol accumulation can cause changes in membrane structure. At the same time, the signaling pathways are also aberrantly activated. Notably, studies reveal that adenomatous polyposis coli (APC) gene mutations in CRC increase cholesterol levels in the inner leaflet of the plasma membrane (IPM) and promote the binding of the Dishevelled (Dvl) protein to cholesterol. This interaction drives β-catenin signaling and accelerates tumor progression.49 Researches have demonstrated that dysregulated cholesterol metabolism is closely linked to TME modulation, immune evasion, and drug resistance, making it a promising therapeutic target for cancer treatment.50,51 Statins, as HMGCR inhibitors, have shown antitumor potential while lowering cholesterol levels. They block cholesterol synthesis and suppress tumor growth by inhibiting HMGCR. Clinical evidence suggests that patients taking statins have a reduced CRC-related mortality rate.52,53 Nanodrugs designed based on cholesterol metabolic characteristics provide new insights for CRC therapy. In an innovative approach, Kim et al22 developed cholesterol-responsive cargo-switching nanoparticles (CSNPs) that encapsulate simvastatin within cyclodextrin-based NPs (Figure 4B). Upon interaction with cholesterol, the cyclodextrin NPs release simvastatin while simultaneously depleting cholesterol. Although originally developed for atherosclerosis, this platform’s cholesterol-depleting and drug-release mechanisms are applicable to CRC. In another study, Liu et al23 designed matrix metalloproteinase-2-responsive tumor-penetrating nanovesicles. These lipid-based nanovesicles deliver the ACAT inhibitor avasimibe to modulate cholesterol metabolism pathways in tumor cells (Figure 4C). These nanovesicles can accumulate in tumors and penetrate into the tumor tissue. The released avasimibe simultaneously blocks cholesterol metabolism in both CD8+ T cells and tumor cells, thereby restoring normal T cell function and inhibiting tumor cell migration. Although both nanoplatforms target cholesterol metabolism, they regulate cholesterol homeostasis through distinct mechanisms. CSNPs-mediated simvastatin delivery inhibits HMGCR to reduce cholesterol biosynthesis and provide an accurate cholesterol exhaustion strategy. Due to simvastatin has a relatively mature clinical application foundation, CSNPs possess high clinical translation potential, but the efficacy may be limited by the heterogeneity of tumor metabolism. The tumor-penetrating nanovesicles carrying avasimibe promote the redistribution of cholesterol by inhibiting the esterification of cholesterol mediated by ACAT. Compared with CSNPs, tumor-penetrating nanovesicles have stronger tumor penetration ability and can simultaneously regulate tumor cells and CD8+ T cells. However, its clinical application faces challenges such as complex preparation of nanodrugs, differences in TME and insufficient safety evaluation. Collectively, statins and ACAT inhibitors suppress tumor initiation and progression by interfering with cholesterol metabolism. Nanodrugs can co-deliver cholesterol metabolism modulators and inhibitors of other signaling pathways, offering new approaches for the comprehensive CRC treatment. Targeting Lipid Storage and Lipolysis Lipid storage and lipolysis are central processes in cellular energy metabolism. Increased lipid uptake and endogenous synthesis in tumor cells lead to abnormal LD accumulation.54 This process helps tumor cells maintain lipid metabolic homeostasis and establish stress defenses, ensuring their survival and proliferation.55 Upon extracellular lipid uptake, FAs are catalyzed by diacylglycerol acyltransferase (DGAT) to generate triglycerides (TAGs). These TAGs are then stored in LDs as energy reserves.56 TAG synthesis and storage play a crucial role in cancer cell growth.57 Inhibiting DGAT significantly triggers apoptotic cell death and limits tumor growth, and relevant inhibitors are currently in the clinical trial phase. Simultaneously, ACAT within the endoplasmic reticulum (ER) membrane converts free cholesterol into CEs. Both CEs and TAGs are stored in LDs, protecting cells from damage caused by free lipid peroxidation.58,59 The storage of cholesterol esters is essential for maintaining lipid homeostasis, as it reduces the toxic effects that free cholesterol may cause. The lipolysis pathway is initiated by adipose triglyceride lipase (ATGL), which degrades LD-stored TAGs. This process continues through hydrolysis by hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MAGL), ultimately releasing FAs.60,61 Notably, ATGL, a key lipolytic enzyme, shows upregulated expression in CRC cells, promoting proliferation and metastasis through enhanced lipolysis.62 Overexpression promotes CRC cell proliferation, while knockout inhibits proliferation and promotes apoptosis, indicating that ATGL may become a potential target for CRC therapy. These findings demonstrate that targeting critical enzymes in lipid storage and breakdown represents an effective strategy to prevent CRC cell growth and dissemination. Evidence indicates that DGAT-specific inhibitors can reduce lipid droplet accumulation and proliferative effects, restore lipid balance, and inhibit tumor growth. AZD7687 and Ervogastaty have already entered clinical trials.63,64 Inhibitors targeting ATGL, such as Atglistatin, have also been successfully developed, they inhibit ATGL activity and reduce fatty acid release.65 A deeper understanding of the reprogramming of lipid storage and degradation provides an important theoretical basis for the development of novel anticancer drugs. Summary and Translational Perspective Targeting lipid metabolism reprogramming provides a potential new strategy for CRC treatment. It exert antitumor effects by intervening with multiple metabolic vulnerabilities, including lipid synthesis, exogenous lipid uptake, cholesterol steady-state regulation, and lipid storage and lipolysis balance. Current research has identified a variety of key metabolic regulatory factors, including ACLY, ACC1, FASN, CD36, HMGCR, ACAT, DGAT and ATGL, which play an important role in promoting tumor cell proliferation, metastasis, immunomodulation and treatment tolerance. It is worth noting that these nanoplatforms have advantages in improving the efficacy of lipid metabolism regulators. They can achieve multi-drug co-delivery, enhance the enrichment of drugs in tumor sites, and reduce systemic toxicity. However, the clinical transformation of lipid metabolism-targeted nanodrugs still faces many challenges. The heterogeneity of tumor metabolism is a major difficulty, and compensatory metabolic adaptation often weakens the therapeutic effect. In addition, insufficient long-term safety evaluation will also limit the clinical transformation of nanodrugs. In the future, nanodrugs with clinical scalability can be designed by integrating multi-target metabolic intervention strategies, which is expected to promote the precise treatment of CRC. Nanodrugs Modulating Lipid-Related Signaling Pathways Lipid metabolites play a regulatory role in key signaling pathways involved in tumorigenesis and progression, including processes such as tumor cell proliferation, metastasis, malignant transformation, EMT, and angiogenesis.66 Conversely, oncogenic signaling pathways can also influence lipid metabolism reprogramming by modulating metabolite levels and transcription factor activity. Multiple oncogenic signaling pathways (such as PI3K/AKT, Wnt/β-catenin, and Notch) interact with and regulate lipid metabolism in CRC, targeting these pathways can indirectly inhibit lipid synthesis or uptake, thereby exerting antitumor effects (Table 2). Table 2Mechanisms of Different Signaling PathwaysSignaling PathwayMediating MechanismEffectPI3K/AKTActivates SREBP transcription factors to upregulate lipogenic enzymes (FASN, ACLY)Enhanced lipid synthesisWnt/β-cateninβ-catenin promotes CD36 transcriptionEnhanced lipid synthesisNotchUpregulates liposynthetase expression and coordinates with stemness maintenance signalingEnhanced lipid synthesis and metabolic reprogramming of stem cells Mechanisms of Different Signaling Pathways PI3K/AKT Signaling Pathway The PI3K/AKT pathway is a crucial intracellular signaling system (Figure 5). Abnormal activation of this pathway drives lipid metabolism reprogramming through multiple mechanisms, exerting malignant effects on CRC initiation and progression.67 Dysregulation of PI3K/AKT signaling primarily stems from either oncogene activation or tumor suppressor gene inactivation, both of them play essential roles in CRC cell growth.68 The pathway can be activated by various extracellular stimuli, including receptor tyrosine kinase (RTK) activation and increased Ras protein activity. Mechanistically, PI3K activation occurs when its p85 subunit binds to phosphotyrosine residues in RTK intracellular domains, thereby releasing its inhibitory effect on the p110 catalytic subunit.69,70 The tumor suppressor PTEN serves as the pathway’s key negative regulator, and its loss also leads to abnormal pathway activation.71 The PTEN gene encodes a bispecific phosphatase with both lipid and protein phosphatase activities, which inhibits AKT activation and downstream signaling by dephosphorylating PIP3 to form PIP2. Activated AKT regulates downstream effectors such as mTOR, which enhances the transcriptional activity of sterol regulatory element-binding proteins (SREBPs).72 This process dramatically upregulates key lipid synthesis enzymes including ACLY, FASN, and ACC, ultimately promoting tumor cell proliferation and invasion.73,74 Consequently, targeting PI3K/AKT signaling has emerged as an effective CRC treatment strategy, which is capable of suppressing tumor growth while inducing apoptosis.75 PI3K/AKT signaling pathway. Several studies have developed nanodrugs targeting the PI3K/AKT pathway. These nanodrugs enhance the effectiveness of both chemotherapy and gene therapy. Li et al76 created pH-sensitive HA-mPEG-Cis NPs. These nanodrugs targeted CD44 receptors and released cisplatin in response to the tumor microenvironment. The study proved this nanoplatform inhibited the PI3K/AKT/mTOR pathway, improving antitumor effects. Similarly, Liu et al77 designed PEG-coated nanocomplexes (PDMAEMA-NP) to deliver miR-128-3p. With MCT1-targeting peptides, the nanodrugs accumulated better in tumors. They blocked both PI3K/AKT and MEK/ERK pathways, working synergistically with 5-fluorouracil to suppress tumor growth and spread. Hu et al78 developed a nanoemulsion co-delivering paclitaxel and a PI3K/Akt/mTOR inhibitor BEZ235 to overcome drug resistance. By reducing Pgp and ABCC1 drug-resistance proteins, it effectively kills resistant colon cancer cells and triggers apoptosis. These nanodrugs achieve precise targeted intervention in the PI3K/AKT signaling pathway. Not only do they enhance drug delivery efficiency and therapeutic specificity, but they also effectively overcome the limitations of traditional chemotherapy and tumor drug resistance, offering new therapeutic approaches for CRC. Wnt/β-Catenin Signaling Pathway The Wnt signaling pathway is a highly conserved cellular transduction system that controls cell progression and specialization, and migration (Figure 6). Mutations in Wnt signaling can cause various diseases.79,80 Without Wnt stimulation, a destruction complex containing AXIN, APC, casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3) is formed. The complex recognizes and phosphorylates β-catenin. Then β-transducin repeat-containing protein (β-TrCP) ubiquitinates β-catenin. This leads to β-catenin degradation by the proteasome.81 Under normal circumstances, the APC and Wnt pathways work together to regulate the stability of β-catenin, ensuring that cells remain in a quiescent state. When Wnt signaling activates, LRP5/6 interacts with Frizzled (FZD). This interaction prevents the destruction complex from functioning. As a result, β-catenin accumulates inside cells.82,83 The accumulated β-catenin then moves into the nucleus. There it binds with T-cell factor (TCF)/lymphoid enhancer factor (LEF). This activates expression of Wnt target genes. Cancer-promoting genes like c-MYC and Cyclin D1 get turned on. These genes stimulate cancer cell proliferation.84 Aberrant Wnt/β-catenin signaling is crucial for CRC. Research shows APC gene loss and β-catenin mutations disrupt this pathway. These disruptions drive CRC development.85,86 Therefore, targeting the Wnt/β-catenin pathway offers a promising strategy. It provides new opportunities for CRC treatment. Wnt/β-catenin signaling pathway. Recent studies show promising advances in using nanodrugs to target the Wnt/β-catenin pathway for CRC treatment. Different nanodrugs demonstrate strong antitumor effects. For example, Rajabi A et al87 developed zymosan-based nanoparticles that released doxorubicin (DOX) in response to pH. These particles significantly reduced expression of Wnt/β-catenin pathway genes, enhancing tumor suppression. Similarly, Wang et al88 created salinomycin nanocrystals (SAL NCs). Compared to free drugs, these nanoparticles showed 1.5–3 times stronger Wnt pathway inhibition and 10 times better cancer stem cell suppression, proving their superior antitumor activity. Mata R et al89 constructed biogenic Abutilon indicum silver/gold nanoparticles (AIAgNPs/AIAuNPs). These particles lower key Wnt pathway molecules like β-catenin and Tcf-4, effectively inhibiting cancer metastasis. These innovative nanodrugs target different stages of the Wnt/β-catenin signaling pathway, boosting drug selectivity, stability, and efficacy in tumors. Consequently, they provide a new solution to overcome the limitations of traditional chemotherapy and cancer stem cell resistance. Notch Signaling Pathway The Notch pathway is another highly conserved signaling system that controls cell-to-cell communication (Figure 7). It plays important roles in cell development, specialization, growth and death.90 Both the ligand and receptor in this pathway are transmembrane proteins, which enables it to mediate direct cell-to-cell signaling. The Notch signaling pathway generates a cascade of events through its interaction with the ligand, it plays a role in determining the direction of differentiation during cell development and influences cell proliferation and apoptosis. The extracellular domain of Notch receptor contains three cysteine-rich LNR repeat sequences and 29–36 tandem epidermal growth factor (EGF) -like repeat sequences. The cytoplasmic region is composed of the RAM domain, anchor protein (ANK) repeat sequence, trans-activating domain (TAD), and PEST sequence.91 When a Notch receptor binds to Delta protein on a neighboring cell, the Notch pathway activates. This binding changes Notch’s shape, allowing ADAM enzymes and γ-secretase to cut the receptor. This cutting releases the Notch intracellular domain (NICD).92 Because NICD has nuclear localization signals, NICD will be transported to the nucleus and bind to CSL transcription factors. The complex formed after binding can recruit co-activators, especially masterbrain-like proteins (MAML).93 The final formed co-activation complex will activate the transcription of a series of downstream target genes, thereby exerting multiple biological functions, including cell differentiation, cell fate determination, stem cell maintenance.94 According to previous studies, the Notch signaling pathway plays a key role in the occurrence of CRC. The highly expressed Notch receptor has a pro-cancer effect. Therefore, inhibiting Notch signaling transduction is a potential treatment option for CRC.95 Notch signaling pathway. Nanodrugs targeting the Notch pathway show great promise for CRC treatment. Shen et al96 developed a berberine delivery system using PEG-PLGA nanoparticles (NPBer). Their study found NPBer blocked Notch signaling while also affecting Wnt, TGF-β and mTOR pathways. This dual action enhanced tumor targeting and anticancer effects. Similarly, Boinpelly et al97 created PLGA nanoparticles carrying α-mangostin (Mang-NPs). These particles specifically inhibited Notch signaling, reducing CRC cell growth, EMT progression, and cancer stem cell renewal. The nanodrug significantly enhances the targeted accumulation of drugs at tumor sites and improves therapeutic efficacy. These effects are achieved by precisely regulating the Notch signaling pathway and its multi-pathway synergistic network. The findings provide important experimental evidence and technical support for the development of new, highly effective, and low-toxicity targeted therapies for CRC. At the molecular level, various signaling pathways interact with one another, forming a complex signaling regulatory network that collectively drives the malignant progression of CRC. When a nanodrug inhibits only a single signaling target, bypass pathways are often upregulated as a compensatory mechanism to maintain cell viability. As a result, the overall therapeutic effect is limited. Numerous studies have demonstrated that targeting multiple signaling pathways can produce synergistic effects, resulting in superior antitumor efficacy. Co-regulation of multiple signaling targets can enhance therapeutic efficacy and offers a foundation for combined targeted strategies. A nanoplatform co‑loading chemotherapeutic agents and multiple signaling pathway inhibitors could be designed to block compensatory pathways. This strategy may represent a promising approach to overcome multidrug resistance in future multi-target nanoplatform development. Signaling Crosstalk Lipid metabolism reprogramming in CRC is not regulated by a single signaling pathway but by a complex network involving multiple interrelated pathways. PI3K/AKT, Wnt/β-catenin and Notch signaling pathways are often abnormally activated in CRC, promoting tumor proliferation, stem cell maintenance, invasion and metastasis.98 The three pathways do not work independently, they form a complex crosstalk network in the development of tumors. The mutual activation between them can enhance the malignant phenotype of tumor cells and promote lipid metabolism reprogramming. Activation of the PI3K/AKT signaling pathway promotes lipid synthesis by regulating the key enzymes of lipid metabolism, and interacts with Wnt/β-catenin signaling pathway. AKT reduces β-catenin degradation by inhibiting the activity of GSK-3β, and promotes its stabilization and nuclear transposition, thus enhancing Wnt signaling output.99 Conversely, Wnt/β-catenin pathway can be used as an upstream activation factor of PI3K/AKT pathway to activate AKT continuously.100 The two form a two-way positive feedback, working together to promote CRC progression. In addition, PI3K/AKT pathway is also closely related to Notch pathway. The activation of AKT can enhance Notch expression, and Notch signaling activates PI3K/AKT by suppressing PTEN phosphorylation.101 Meanwhile, Notch and Wnt/β-catenin pathway work together to maintain cancer stem cells and promote tumor cell proliferation.102 The interaction among these pathways suggests that targeting a single signaling axis may be insufficient due to compensatory activation of alternative pathways. A comprehensive understanding of signaling pathway crosstalk will help find new combination therapy targets. Summary and Translational Perspective Lipid metabolism-associated signaling pathways, including PI3K/AKT, Wnt/β-catenin, and Notch, form an interconnected regulatory network that drives lipid metabolic reprogramming in CRC. These signaling pathways regulate the expression and activity of key lipid metabolic enzymes. The extensive crosstalk among these pathways contributes to cell proliferation, stemness maintenance, invasion and metastasis. Compared to targeting a single signaling pathway, nanodrugs can be designed to deliver multiple pathway inhibitors and lipid metabolism regulators at the same time. Potential intervention targets include PI3K/AKT, Wnt/β-catenin, Notch, as well as key metabolic enzymes like FASN, ACLY, or HMGCR (Figure 8). Crosstalk between lipid metabolism reprogramming and oncogenic signaling pathways in cancer. The Wnt/β-catenin, PI3K/AKT, and Notch pathways are interconnected and converge on lipid metabolism reprogramming, promoting malignant tumor behaviors. Key lipid metabolic nodes, including CD36, ACLY, ACC, FASN, ACAT, HMGCR, and DGAT, represent potential therapeutic targets. Nanomedicine strategies targeting these pathways include PI3K, AKT, and mTOR inhibitors; β-catenin and TCF inhibitors; γ-secretase inhibitors and Notch siRNA; ACLY, ACC, and FASN inhibitors; and HMGCR and ACAT inhibitors. Nanodrugs targeting lipid-related signaling pathways enable precise delivery of pathway inhibitors, improving tumor-specific accumulation. These nanodrugs may enhance antitumor efficacy and reduce systemic toxicity by simultaneously regulating oncogenic signaling networks and metabolic vulnerabilities. However, the complexity of signaling interactions, adaptive resistance, and safety evaluation limit clinical translation. Future development of multifunctional nanoplatforms capable of integrating multi-pathway regulation may offer new opportunities for CRC precision treatment. Translational Perspectives and Challenges Although numerous nanodrugs targeting lipid metabolism have demonstrated significant efficacy during the preclinical phase, their clinical application still encounters multiple limitations (Table 3). The biocompatibility and pharmacokinetic properties of nanodrugs are considered the primary barriers to clinical translation. Upon entering a biological system, nanodrugs interact with proteins to form a protein corona, which may alter the drug release kinetics. For example, in liposomal nanoparticles, the formation of a protein corona alters the drug release profile, and premature drug release reduces its efficacy. In addition, nanodrugs are recognized and cleared by the immune system, which significantly reduces the circulation time of the drug and its bioavailability. The long-term in vivo safety of nanodrug materials also requires close attention, as some carriers may have adverse effects. For example, degradation products of PLGA nanoparticles may accumulate locally, thereby triggering inflammation. The long-term accumulation of inorganic nanodrugs such as gold and silver in the body can cause toxicity and adverse immune reactions. Therefore, there is a need to develop highly effective, low-toxicity nanodrugs for clinical translation. Table 3The Main Translational ChallengesTranslational ChallengeSpecific IssueEffectProtein corona formationInteraction of nanoparticles with proteins in biological fluids may alter drug release kineticsPremature drug release and reduced therapeutic efficacyImmune clearanceRecognition and elimination of nanoparticles by the immune systemShortened circulation time and reduced bioavailabilityPLGA degradationLocal accumulation of degradation products from PLGA nanoparticlesPotential induction of local inflammatory responses and safety concernsNanoparticle accumulationPersistent accumulation of gold- or silver-based nanoparticles in tissuesPotential toxicity and adverse immune responsesAbbreviations: CRC, colorectal cancer; TME, tumor microenvironment; FAO, fatty acid oxidation; CAFs, cancer-associated fibroblasts; DNL, de novo lipogenesis; FA, fatty acid; ACLY, ATP citrate lyase; ACC, acetyl-CoA carboxylase; FASN, fatty acid synthase; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; CFNA, carrier-free nanoagent; PUFA, polyunsaturated fatty acid; FATP, fatty acid transport protein; FABP, fatty acid binding protein; EMT, epithelial-mesenchymal transition; SCD, stearoyl-CoA desaturase; MVA, mevalonate; HMGCR, HMG-CoA reductase; LDLR, low-density lipoprotein receptor; CE, cholesterol ester; ACAT, acyl-CoA cholesterol acyltransferase; LD, lipid droplet; APC, adenomatous polyposis coli; IPM, inner leaflet of the plasma membrane; Dvl, Dishevelled; CSNPs, cargo-switching nanoparticles; TAG, triglyceride; DGAT, diacylglycerol acyltransferase; ATGL, adipose triglyceride lipase; HSL, hormone-sensitive lipase; MAGL, monoacylglycerol lipase; RTK, receptor tyrosine kinase; SREBP, sterol regulatory element-binding protein; CK1, casein kinase 1; GSK3, glycogen synthase kinase 3; β-TrCP, β-transducin repeat-containing protein; FZD, frizzled; TCF, T-cell factor; LEF, lymphoid enhancer factor; DOX, doxorubicin; EGF, epidermal growth factor; ANK, anchor protein; TAD, trans-activating domain; NICD, Notch intracellular domain; MAML, masterbrain-like protein. The Main Translational Challenges Abbreviations: CRC, colorectal cancer; TME, tumor microenvironment; FAO, fatty acid oxidation; CAFs, cancer-associated fibroblasts; DNL, de novo lipogenesis; FA, fatty acid; ACLY, ATP citrate lyase; ACC, acetyl-CoA carboxylase; FASN, fatty acid synthase; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; CFNA, carrier-free nanoagent; PUFA, polyunsaturated fatty acid; FATP, fatty acid transport protein; FABP, fatty acid binding protein; EMT, epithelial-mesenchymal transition; SCD, stearoyl-CoA desaturase; MVA, mevalonate; HMGCR, HMG-CoA reductase; LDLR, low-density lipoprotein receptor; CE, cholesterol ester; ACAT, acyl-CoA cholesterol acyltransferase; LD, lipid droplet; APC, adenomatous polyposis coli; IPM, inner leaflet of the plasma membrane; Dvl, Dishevelled; CSNPs, cargo-switching nanoparticles; TAG, triglyceride; DGAT, diacylglycerol acyltransferase; ATGL, adipose triglyceride lipase; HSL, hormone-sensitive lipase; MAGL, monoacylglycerol lipase; RTK, receptor tyrosine kinase; SREBP, sterol regulatory element-binding protein; CK1, casein kinase 1; GSK3, glycogen synthase kinase 3; β-TrCP, β-transducin repeat-containing protein; FZD, frizzled; TCF, T-cell factor; LEF, lymphoid enhancer factor; DOX, doxorubicin; EGF, epidermal growth factor; ANK, anchor protein; TAD, trans-activating domain; NICD, Notch intracellular domain; MAML, masterbrain-like protein. In order to overcome these obstacles at the conversion level, it is necessary to promote the clinical development of targeted lipid metabolism nanodrugs from many aspects such as nanodrug design, preparation process and safety evaluation. Nanodrugs with good biocompatibility, controlled degradability and low immunogenicity help reduce protein corona formation, immune clearance and long-term accumulation in the body. At the same time, scalable and repeatable production processes that meet good production specifications (GMP) are crucial to ensure the consistency of nanodrug quality, including key parameters such as particle size, drug delivery efficiency, stability and biological activity. Advanced manufacturing technology and standardized quality control system are also important foundations for promoting the regulatory approval of nanodrugs. In addition, pharmacokinetics, biological distribution, toxicity and long-term safety still need to be systematically evaluated to meet the requirements of clinical transformation and supervision. Although some nanodrug preparations have entered the clinical trial stage, most of the nanodrugs reprogrammed for CRC lipid metabolism are still in the preclinical research stage, and their safety and therapeutic effects still need to be verified through further animal experiments and clinical research. Conclusion Lipid metabolic reprogramming is one of the hallmark features of CRC, it drives tumor progression, immune evasion, and therapy resistance. Among various lipid-regulatory pathways, the CD36 pathway which mediates aberrant lipid uptake has great impact on CRC metastasis and tumor aggressiveness. CD36 high expression enhances fatty acid absorption and stimulates EMT. In a nutrient-deprived tumor microenvironment, it also promotes metabolic adaptation. Simultaneously, lipid synthesis mediated by enzymes such as FASN, ACC, and ACLY plays a critical role in tumor growth and development. These upregulated key enzymes drive the production of endogenous fatty acids, promoting rapid proliferation of tumor cells. PI3K/AKT, Wnt/β-catenin and Notch signaling pathways globally regulate both endogenous lipid synthesis and exogenous lipid uptake. These pathways are often co-activated in CRC and contribute to a feedback loop sustaining oncogenic growth. Therefore, targeting both lipid uptake and synthesis while intervening in oncogenic signaling pathways is regarded as a viable and potential strategy for CRC treatment. We envision that future efforts in CRC lipid-targeted nanodrugs will focus on the development of multifunctional nanodrugs. These nanodrugs are capable of co-delivering inhibitors of CD36, lipogenic enzymes and oncogenic signaling pathway modulators. In addition, the nanodrugs should precisely control the timing and location of drug release. Such nanodrugs may overcome tumor heterogeneity and reduce compensatory pathway activation, leveraging the synergistic antitumor effects of drugs. Previous CRC therapeutic approaches targeted a single pathway, whereas nanodrugs enable the simultaneous inhibition of lipid metabolism and signaling pathways. This shift will significantly improve treatment outcomes for advanced and refractory CRC. However, the clinical transformation of lipid-targeted nanodrugs still faces many limitations. Nanodrugs targeting CD36, ACLY, ACC and FASN may be affected by the heterogeneity of tumor metabolism and the activation of compensatory metabolic pathways. At the same time, attention should be paid to the important role of lipid metabolism in normal tissue physiological activities and the resulting potential toxicity. Nanodrugs for PI3K/AKT, Wnt/β-catenin and Notch signaling pathways is also affected by factors such as complex inter-pathway interference, adaptive drug resistance and insufficient tumor targeting specificity. Artificial intelligence (AI)-assisted nanomedicine provides new research means for the optimization of nanoplatforms, which can be used to predict the interaction between drugs and carriers, the physicochemical properties of nanodrugs and potential therapeutic responses. At the same time, bionic nanodrugs based on natural cells or extracellular vesicles have good biocompatibility and may improve immune escape and tumor targeting. Combining these emerging technologies with precise treatment strategies may further improve the targeting and therapeutic effect of nanodrugs, and provide a new research direction for the individualized treatment of CRC and the clinical transformation of nanodrugs. Funding Statement This work was supported by the Joint Project of Science and Technology Committee of Yangpu District and Health Commission of Shanghai Yangpu District (No. YPQ202304) and the hospital research grant awarded in 2023 (No. YJZD02) from Yangpu District Shidong Hospital. Furthermore, additional funding was provided by Natural Science Foundation of Jiangsu Province (No. BK20240466), the China Postdoctoral Science Foundation under Grant Number 2024M763181, and the Excellent Postdoctoral Program in Jiangsu Province (2024ZB076). Disclosure The authors report no conflicts of interest in this work. References